It was found that mutations in the miR-520a- and miR-525a-binding sites in the 3′UTR of PIK3CA could improve the sensitivity of CRC cell lines to an inhibitor of Akt-dependent signaling, saracatinib [113]. This evidence concerns the gene PIK3CA and colorectal carcinoma.